ADARx Pharmaceuticals priced an upsized initial public offering of 26.25 million primary shares at $17 each, for approximately $446.3 million in gross proceeds before expenses. Trading began on Nasdaq on September 25 under ADRX,…
C4 Therapeutics reported biomarker evidence that cemsidomide plus dexamethasone activated CD8 T cells and reprogrammed natural-killer cells across 62 heavily pretreated myeloma patients, with stronger effects at 75 and 100 micrograms. In the elranatamab…
In the initial 20-patient cohort A subgroup of Phase 2 CARTITUDE-2, ten patients remained alive and progression-free five years after one cilta-cel infusion and without maintenance therapy. At 60.7 months median follow-up, five-year overall…
Finland-based Kasvu Therapeutics raised a €30 million Series A led by Hadean Ventures, with Tesi, Innovestor and other Finnish science investors participating. Proceeds are intended to take KTX-0141, a small-molecule positive allosteric modulator of…
A peer-reviewed Phase 1 study of anitocabtagene autoleucel reported responses in all 38 treated patients with heavily pretreated relapsed or refractory multiple myeloma, including 79% complete responses. At 38.1 months median follow-up, median progression-free…
Roche agreed to pay Atavistik Bio $70 million upfront for a multi-target research collaboration using Atavistik’s AMPS platform to discover allosteric small molecules in cardiovascular, renal and metabolic disease. Atavistik may receive up to…
The FDA approved lirafugratinib, branded Lyrfigtu, for adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement. In the single-arm REFOCUS study of 116 FGFR-inhibitor-naive patients, independently reviewed…
InnoCare Pharma entered a research collaboration and license agreement with Eli Lilly covering compounds against as many as five undisclosed targets. InnoCare may receive up to $100 million in upfront and near-term payments, approximately…
Kyverna reported 12-month durability from the 26-patient KYSA-8 registrational study in stiff person syndrome and longer follow-up from seven generalized myasthenia gravis patients. Median timed 25-foot walk improvement in SPS was 49% at Month…
Ligand committed up to $47 million to AvenCell Therapeutics. Up to $41 million will be provided in exchange for mid-single-digit to low-double-digit royalties on worldwide sales across current and future AvenCell assets, and up…
